Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lipella Pharmaceuticals, Inc. (LIPO)
NASDAQ:LIPO
RESEARCH TOOLSreports
Holding LIPO?
Track your performance easily
LIPO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.32 - $2.71
Previous Close$0.52
Volume1.40M
Average Volume (3M)3.46M
Market Cap
$4.16M
Enterprise Value$3.07M
Total Cash (Recent Filing)$1.19M
Total Debt (Recent Filing)$93.68K
Price to Earnings (P/E)―
Beta-1.16
Next Earnings
May 15, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding8,004,636
10 Day Avg. Volume653,751
30 Day Avg. Volume3,464,055
Standard Deviation0.27
R-Squared0.00118
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.33
Price to Sales (P/S)4.02
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.67
Enterprise Value/Gross Profit6.82
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$2.00Price Target Upside284.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Lipella Pharmaceuticals, Inc. News
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsThe prior P2a study reported positive results for moderate-to-severe hemorrhagic cystitis patients treated with LP-10, with improvements in various urinary symptoms.
Market OpportunityLarge market opportunity for LP-10 due to lack of approved treatments for hemorrhagic cystitis, with positive P2 results validating the improved safety and delivery.
Regulatory SupportLP-410 granted orphan drug designation for oral GvHD, indicating a supportive regulatory environment and potential market exclusivity benefits.
Bears Say
Corporate GovernanceProxy Fight: Losing to Erez Could Derail Momentum.
Financial PerformanceLipella ended the fiscal year with $3.3M in cash and expects to need additional capital later, indicating a potential for future dilution or financing needs.
FundingThe company will need to raise additional capital to fund the upcoming study for LP-10.
---
Ownership Overview
22.19% Insiders
0.95% Mutual Funds
7.18% Other Institutional Investors
69.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LIPO FAQ
What was Lipella Pharmaceuticals, Inc.’s price range in the past 12 months?
Lipella Pharmaceuticals, Inc. lowest stock price was $0.32 and its highest was $2.71 in the past 12 months.
What is Lipella Pharmaceuticals, Inc.’s market cap?
Currently, no data Available
When is Lipella Pharmaceuticals, Inc.’s upcoming earnings report date?
Lipella Pharmaceuticals, Inc.’s upcoming earnings report date is May 15, 2023 which is 468 days ago.
How were Lipella Pharmaceuticals, Inc.’s earnings last quarter?
Lipella Pharmaceuticals, Inc. released its earnings results on Mar 31, 2023. The company reported -$0.186 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.186.
Is Lipella Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Lipella Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Lipella Pharmaceuticals, Inc. pay dividends?
Lipella Pharmaceuticals, Inc. does not currently pay dividends.
What is Lipella Pharmaceuticals, Inc.’s EPS estimate?
Lipella Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lipella Pharmaceuticals, Inc. have?
Lipella Pharmaceuticals, Inc. has 8,004,636 shares outstanding.
What happened to Lipella Pharmaceuticals, Inc.’s price movement after its last earnings report?
Lipella Pharmaceuticals, Inc. reported an EPS of -$0.186 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.622%.
Which hedge fund is a major shareholder of Lipella Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in LIPO
---
Lipella Pharmaceuticals, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (284.99% Upside)
$2.00 (284.99% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.17%
12-Months-Change
Fundamentals
Return on Equity
-171.56%
Trailing 12-Months
Asset Growth
-37.41%
Trailing 12-Months
Company Description
Lipella Pharmaceuticals, Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company's lead product includes LP-10 and LP-310.
---
LIPO Stock 12 Month Forecast
Average Price Target
$2.00
▲(284.99% Upside)
Best Analysts Covering LIPO
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-35.48%
assigned a buy rating 11 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -35.48% per trade.
---